Clinical Efficacy of Antianlotinib Combined with Immune Checkpoint Inhibitors in the Treatment of Advanced Non-Small-Cell Lung Cancer and Its Effect on Serum VEGF, CEA, and SCC-Ag

Table 3

T lymphocyte subsets and serum level of vascular endothelial growth factor before and after therapy.

Subject	Study group		Control group
	Before treatment	After treatment	Before treatment	After treatment
VEGF (ng/L)		^#		^#
CEA (μg/L)		^#		^#
SCC-Ag (μg/L)		^#		^#
CD3^+		2^#		^#
CD4^+		^#		^#
CD8^+		^#		^#
CD4^+/CD8^+		^#		^#

, compared with the control group; ^#, compared with before treatment.